Back to Search
Start Over
Effect of bevacizumab added preoperatively to oxaliplatin on liver injury and complications after resection of colorectal liver metastases
- Source :
- Journal of Surgical Oncology, 106(7), 892-897. Wiley-Liss Inc.
- Publication Year :
- 2012
-
Abstract
- Background: Chemotherapy (CTx) before resection of colorectal liver metastases (CRLM) may cause hepatic injury and postoperative complications. To ascertain whether adding bevacizumab, a monoclonal antibody against VEGF, to oxaliplatin-based CTx has an influence on liver injury and postoperative complications. Methods: Patients with CRLM who received neoadjuvant CTx and underwent resection between 2003 and 2008 were analyzed whether or not they received bevacizumab added to oxaliplatin-based CTx. Results: The total study group existed of 104 patients: 53 patients received oxaliplatin-based CTx and 51 patients received oxaliplatin-based CTx and bevacizumab. The overall complication rate (29%) was not significantly different between the two groups. The bevacizumab group exhibited less moderate sinusoidal dilatation (8% vs. 28%, P = 0.01). No difference in complication rate was found between patients given fewer than six cycles of oxaliplatin-based CTx and those given six or more cycles, or Conclusion: Bevacizumab added to oxaliplatin-based CTx may protect against moderate sinusoidal dilatation without significantly influencing morbidity. Neither duration of oxaliplatin-based CTx nor the time interval between cessation of oxaliplatin-based CTx and surgery were associated with postoperative complications. J. Surg. Oncol. 2012; 106:892897. (C) 2012 Wiley Periodicals, Inc.
- Subjects :
- bacterial infections and mycoses
Subjects
Details
- ISSN :
- 00224790
- Database :
- OpenAIRE
- Journal :
- Journal of Surgical Oncology, 106(7), 892-897. Wiley-Liss Inc.
- Accession number :
- edsair.narcis........4409a7483562554c0b91aae87c0bd226